[Click eStock] "Syntekabio, Korea's Only AI Drug Development Company... Time to Pay Attention"

On the 28th, SK Securities analyzed that Syntekabio has entered a phase where global artificial intelligence (AI) interest trends, government policies, and individual growth momentum overlap.

Syntekabio, established in 2009 and listed on the KOSDAQ market in 2019, is the first and only AI drug development company listed in Korea. Syntekabio's revenue structure consists of ▲ AI drug development platform usage fees ▲ license-out (L/O) revenue from effective substances discovered through its own AI drug development platform.

Heo Seonjae, a researcher at SK Securities, explained in a report on the day, "The reason to pay attention to Syntekabio now is that from the second half of this year, through ▲ sales from the cloud AI drug development platform ▲ L/O of self-discovered candidate substances ▲ the start of the data voucher project, the issue of 'performance gaps due to lack of research results,' which has been considered a major drawback of the company until now, is expected to be resolved."

Researcher Heo added, "The STB Cloud service equipped with the synthetic drug candidate discovery platform Deep Matcher was launched in the US in the fourth quarter of last year, marking a full-scale entry into the global market," and "to respond to full-scale demand, the number of supercomputers will be expanded to 10,000 units by the end of the year."

He also stated, "For the first time since its establishment, the possibility of entering clinical trials and L/O has emerged, and in the short term, competitiveness in the AI drug development sector, which has not been demonstrated so far, will be proven," and "from next year, a series of L/Os is expected to be possible, so steady momentum will continue from the second half of this year."

He added, "Since it is entering a phase where the huge global trend of AI + government policies + individual stock growth momentum overlap, it is highly necessary to pay attention to Syntekabio from now on."

This content was produced with the assistance of AI translation services.